 |
Aegera Therapeutics is building an integrated world-class biotechnology company focused on signal transduction and apoptosis. Formed by the merger of Apoptogen and Exogen Neurosciences in May 2000, Aegera's primary therapeutic focus is in apoptosis control: killing cancer cells by inducing apoptosis, rescuing neurons from cell death, and implanting stem cells to restore function.
Neurology and cancer are two of the fastest growing unsatisfied segments in the pharmaceutical industry with large disease profit pools. Central nervous system (CNS) diseases is the Number 2 Therapeutic Area. Aegera's neurotrophin surrogate program |
